Study Description: 2-Octyl Cyanoacrylate (Dermabond) use in neonatal circumcision are being practiced to prevent complications; however, no randomized controlled trials was ever done to assess efficacy and safety. This is a single-centered, randomized clinical trial to assess the efficacy and safety of 2-Octyl Cyanoacrylate (Dermabond) application in neonatal circumcision to prevent complication. Primary Objective: To determine the efficacy and safety of 2-Octyl Cyanoacrylate (Dermabond) application versus control in neonatal circumcision to prevent post-procedural complication. Secondary Objectives: 1. To assess post-procedural pain score difference between with versus without 2-Octyl Cyanoacrylate (Dermabond) application in neonatal circumcision 2. To assess parents' satisfaction and cosmesis post-neonatal circumcision with versus without 2-Octyl Cyanoacrylate (Dermabond) application. Endpoints: Primary Endpoint: Complication rates post-neonatal circumcision within 180 days with the following complication in specific or in composite ⦁ Bleeding requiring hemostatic intervention (suturing, dermabond application, silver nitrite application, pressure bandage) * Infection requiring antibiotic administration or wound drainage * Excess skin as assessed by parents satisfaction * Meatal stenosis * Adhesion requiring surgical correction. Secondary Endpoints: 1. pain score within 5 min and 30 minutes postneonatal circumcision using the FLACC score by parents and MBPS scale by a medical allied personnel. 2. Parents satisfaction as determined by a simple 10-score liked scale and cosmesis assessment scale within 24hrs and within 30 days post-neonatal circumcision. Complication rates detailed above in specific time points clustered according to (within 24 hrs, within 2 weeks, within 30 days, within 30 to 180 days). Study Population: 280 male neonates (140 each intervention groups) who are eligible for neonatal circumcision with no other medical co-morbidities. Intervention: 2-Octyl Cyanoacrylate (Dermabond) 0.5ml/ sticks) topical application around post-circumcision site subcoronal area.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
280
Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
The Hospital for Sick Children
Toronto, Ontario, Canada
RECRUITINGComplication rates (Composite)
Composite complication rates post-neonatal circumcision within 180 days following neonatal circumcision
Time frame: 180 days post neonatal circumcision
Pain score (FLACC) by Parents
pain score within 5 minutes post-neonatal circumcision using the FLACC score by parents. (Higher Score is Worse)
Time frame: 5 minutes and 30 minutes
Pain score (MBPS) by Medical Personnel
pain score within 5 minutes and 30 minutes post-neonatal circumcision using the MBPS scale by a medical allied personnel. (Higher Score is Worse)
Time frame: 5 minutes and 30 minutes
Parents Satisfaction
Parents satisfaction as determined by a simple 10-score liked scale and cosmetic assessment scale within 24hours and within 30 days post-neonatal circumcision
Time frame: within 24 hours and 30 days post neonatal circumcision
Complication rates (specific case characteristics)
Complication rates post-neonatal circumcision
Time frame: within 24 hours, within 2 weeks, within 30 days within 30 to 180 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.